BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.30 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 2.95M

Average 4.85M

BCRX Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026

Change in working capital turns negative

Q2 FY2026 change in working capital was -$3.11M, compared with $2.38M a year earlier. Trailing-twelve-month change in working capital was -$71.66M. Over 3 fiscal years it compounded at -1.2% a year.

Context

  • Change in working capital amounted to 6.5% of revenue in FY2025, down 12.9 pp from a year earlier.
  • Change in working capital grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly change in working capital holds near -$3.11M or moves back toward the trailing-twelve-month quarterly average of -$17.91M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$3.11M-95.6% QoQ
Last fiscal yearDec 2025
-$56.9M-34.8% YoY
LTMJun 2026
-$71.66M-10.7% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-231.0%——
1 year-34.8%——
3-year CAGR-1.2%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(56.9M) USD
Year-over-year change
+34.8%

Change in Working Capital vs competitors

How BCRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.7% is the 2nd highest of 4, against a peer median of -56.1%.
  • Change in working capital amounts to 7.6% of revenue for BCRX, versus a peer median of 108.7%.
BCRX Competitors
Change in Working Capital for BCRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$71.66M USD-10.7%-1.2%7.6%
VIRVir Biotechnology, Inc.LTM Mar 2026$71.19M USD-394.2%—108.7%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$13.89M USD+159.9%——
PHVSPharvaris N.V.LTM Sep 2026€2.93M EUR-56.1%-3.1%—
Peer median (excluding BCRX) —-56.1%-3.1%108.7%

Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(184.06M)(247.12M)(226.54M)(88.88M)263.86M
Depreciation & Amortization777K1.44M1.66M1.25M1.39M
Deferred Income Tax00000
Stock-Based Compensation34.64M44.7M55.62M65.41M85.07M
Change in Working Capital8.12M(58.95M)(32.4M)(87.28M)(56.9M)
Accounts Receivables(20.82M)(21.47M)(6.1M)(22.7M)(36.81M)
Inventory(8.77M)(12.42M)(1.45M)(4.16M)(1.64M)
Accounts Payables39.41M(22.36M)(16.81M)(62.38M)57.8M
Other Working Capital(1.7M)(2.69M)(8.05M)1.96M(76.26M)
Other Non-Cash Items(1.64M)98.07M106.53M57.48M36.46M
Operating Cash Flow(142.16M)(161.85M)(95.14M)(52.02M)329.88M
Capital Expenditures(2.39M)(1.35M)(2.17M)(1.12M)(2.47M)
Acquisitions (Net)0000(6.18M)
Purchases of Investments(10.01M)(244.28M)(514.41M)(266.76M)(262.24M)
Sales of Investments28.2M117.4M385.08M320.48M256.65M
Other Investing Activities0000550K
Investing Cash Flow15.8M(128.24M)(131.5M)52.59M(13.69M)
Debt Repayment293.87M73.07M58.38M(1.7M)(332.77M)
Common Stock Issued50.06M190K342K34K9.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities15.73M14.77M(26.24M)(4.09M)(8.85M)
Financing Cash Flow359.67M88.03M32.49M(5.76M)(332.44M)
Effect of Forex Changes71K566K362K(936K)(87.07M)
Net Change in Cash233.39M(201.5M)(193.79M)(6.12M)(103.32M)
Free Cash Flow(144.54M)(163.2M)(97.31M)(53.14M)327.41M

BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Intrinsic Alpha fair value

Locked

Current Price

$7.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.